Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?
- Friday, March 5, 2021, 7:14
- Market
- Add a comment
The stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation, has seen a 17% drop over the last ten trading days, while it’s down 11%…
About the Author
admin123 has written 23453 stories on this site.
